619 related articles for article (PubMed ID: 30814139)
1. Fibrosing interstitial lung diseases: knowns and unknowns.
Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
[TBL] [Abstract][Full Text] [Related]
2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
[TBL] [Abstract][Full Text] [Related]
4. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
6. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
7. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Fischer A; Distler J
Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
[TBL] [Abstract][Full Text] [Related]
8. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
[TBL] [Abstract][Full Text] [Related]
10. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
[TBL] [Abstract][Full Text] [Related]
11. Acute exacerbations of progressive-fibrosing interstitial lung diseases.
Kolb M; Bondue B; Pesci A; Miyazaki Y; Song JW; Bhatt NY; Huggins JT; Oldham JM; Padilla ML; Roman J; Shapera S
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578331
[TBL] [Abstract][Full Text] [Related]
12. Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
Wongkarnjana A; Scallan C; Kolb MRJ
Curr Opin Pulm Med; 2020 Sep; 26(5):436-442. PubMed ID: 32657838
[TBL] [Abstract][Full Text] [Related]
13. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
15. The natural history of progressive fibrosing interstitial lung diseases.
Kolb M; Vašáková M
Respir Res; 2019 Mar; 20(1):57. PubMed ID: 30871560
[TBL] [Abstract][Full Text] [Related]
16. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
17. [Antifibrotic therapy and progressive lung fibrosis].
Fellrath JM
Rev Med Suisse; 2020 Jun; 16(698):1256-1260. PubMed ID: 32558455
[TBL] [Abstract][Full Text] [Related]
18. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
20. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
